Bangladesh TB Leaders Build Momentum for Shorter, Safer Drug-Resistant Tuberculosis Treatment
Capacity building program in the Philippines empowers Bangladesh NTP managers to scale up BPaL and…
New Study Affirms Financial and Public Health Advantages of Treating Drug-Resistant TB with BPaL-Based Regimens in India
A new economic evaluation has added powerful evidence to the already strong case for wide,…
Indonesian Ministry of Health and TB Alliance Enter Strategic Partnership to Advance Innovations in TB and Mycobacterial Diseases
Collaboration Aims to Strengthen Health Systems and Accelerate Development of Next-Generation Treatments JAKARTA (July 30,…
TB Experts Rally Around New, Shortened TB Treatments
Regional meeting in Peru convened by PeerLINC, a global peer-to-peer initiative, brings together 20 countries…
Price of Key DR-TB Medicine Drops 25% as TB Alliance’s Multi-Manufacturer Strategy Expands Access
TB Alliance’s third licensed manufacturer makes pretomanid available through the Global Drug Facility, further improving…
Afrigen Biologics and Vaccines: A Catalyst in mRNA Technology and LMIC Capacity Strengthening
Afrigen Biologics and Vaccines embodies the spirit of equitable healthcare innovation, scientific advancement, and regional…
The Biggest Challenge to Ending TB is not Scientific
Statement from TB Alliance on World TB Day For most of human history, tuberculosis (TB)…
PeerLINC Recognizes One Year of Transforming Drug-Resistant TB Treatment Through Faster, More Easily Accessible Technical Assistance
The PeerLINC Knowledge Hub, an innovative peer-to-peer initiative that connects experts from countries that rapidly…
Mel Spigelman on the future of TB treatment and the evolution of TB Alliance
2025 marks the 25th anniversary of TB Alliance. Throughout the year, we are sitting down…